Lantern Pharma (NASDAQ:LTRN – Get Free Report) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.46) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 9:30 AM ET.
Lantern Pharma Price Performance
NASDAQ LTRN opened at $2.71 on Wednesday. The firm has a market capitalization of $30.30 million, a price-to-earnings ratio of -1.55 and a beta of 1.53. The company has a 50 day simple moving average of $3.09 and a 200-day simple moving average of $3.62. Lantern Pharma has a 52-week low of $2.45 and a 52-week high of $5.74.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of Lantern Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lantern Pharma in a report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $25.00.
Institutional Investors Weigh In On Lantern Pharma
Several institutional investors and hedge funds have recently added to or reduced their stakes in LTRN. Geode Capital Management LLC raised its holdings in Lantern Pharma by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 96,742 shares of the company’s stock valued at $293,000 after acquiring an additional 4,661 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Lantern Pharma by 10.3% during the fourth quarter. Renaissance Technologies LLC now owns 110,400 shares of the company’s stock valued at $335,000 after purchasing an additional 10,300 shares during the period. Cetera Investment Advisers acquired a new position in shares of Lantern Pharma in the fourth quarter valued at $37,000. XTX Topco Ltd bought a new position in Lantern Pharma in the second quarter worth $40,000. Finally, CIBC Private Wealth Group LLC acquired a new stake in Lantern Pharma during the fourth quarter worth $47,000. 28.62% of the stock is currently owned by institutional investors and hedge funds.
About Lantern Pharma
Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.
The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.
Further Reading
- Five stocks we like better than Lantern Pharma
- New Copper-Rich “Kraken” Zone Discovered
- Silver Is the New Oil—And the World’s Running Dry
- America’s 1776 happening again
- 3 Signs You May Want to Switch Financial Advisors
- Silver’s squeeze is tightening – opportunity forming
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
